Day One Biopharmaceuticals Advancing Targeted Therapies for Pediatric Glioma
| BCTX Stock | USD 4.18 0.08 1.95% |
Slightly above 53% of Briacell Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Briacell Therapeutics Corp suggests that many traders are impartial. Briacell Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Briacell Therapeutics' earnings reports, geopolitical events, and overall market trends.
Briacell |
We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a look at where Day One Biopharmaceuticals stands against other biggest stocks with negative beta to consider. Beta is a measureament of market risk or volatility that indicates how much the price
Read at finance.yahoo.com
 |
Briacell Therapeutics Fundamental Analysis
We analyze Briacell Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Briacell Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Briacell Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
Briacell Therapeutics is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Briacell Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Briacell Therapeutics stock to make a market-neutral strategy. Peer analysis of Briacell Therapeutics could also be used in its relative valuation, which is a method of valuing Briacell Therapeutics by comparing valuation metrics with similar companies.
Peers
Briacell Therapeutics Related Equities
| PDSB | PDS Biotechnology | 22.22 | ||||
| HEPA | Hepion Pharmaceuticals | 6.67 | ||||
| ELEV | Elevation Oncology | 1.85 | ||||
| INZY | Inozyme Pharma | 1.68 | ||||
| TERN | Terns Pharmaceuticals | 1.35 | ||||
| MREO | Mereo BioPharma | 2.78 | ||||
| XFOR | X4 Pharmaceuticals | 6.82 | ||||
| HOOK | Hookipa Pharma | 7.36 | ||||
| DAWN | Day One | 16.50 |
Additional Tools for Briacell Stock Analysis
When running Briacell Therapeutics' price analysis, check to measure Briacell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Briacell Therapeutics is operating at the current time. Most of Briacell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Briacell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Briacell Therapeutics' price. Additionally, you may evaluate how the addition of Briacell Therapeutics to your portfolios can decrease your overall portfolio volatility.